zenuzolac   Click here for help

GtoPdb Ligand ID: 11682

Synonyms: (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid | GIT-027 | GIT-27 | GIT27 | GLS-1027 | GLS1027 | rac-[(5R)-3-phenyl-4,5-dihydro-1,2-oxazol-5-yl]acetic acid | VGX-1027 | VGX1027
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: We obtained the chemical structure for zenuzolac from WHO Proposed list 125 of July 2021, in which it is described as an anti-inflammatory. The INN represents the racemic (rac) mixture of (R) and (S) enantiomers. We show the molecule without specified stereochemistry to represent the mixture. We have mapped this to PubChem CID 10798271. Synonyms from the PubChem entry associate the structure with research code VGX-1027 (VGX Pharmaceuticals). VGX-1027 is an immunomodulatory compound that downregulates proinflammatory cytokine production and NF-κB and MAP kinase activation [1,4-5].

COVID-19: Zenuzolac (re-named as GLS-1027) is being evaluated to determine its potential to reduce SARS-CoV-2-induced pulmonary inflammation (pneumonitis).
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 58.89
Molecular weight 205.07
XLogP 1.93
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(=O)CC1ON=C(C1)c1ccccc1
Isomeric SMILES C1C(ON=C1c1ccccc1)CC(=O)O
InChI InChI=1S/C11H11NO3/c13-11(14)7-9-6-10(12-15-9)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,13,14)
InChI Key MUFJHYRCIHHATF-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Two safety, tolerability and pharmacokinetics clinical studies of VGX-1027 in healthy subjects have been completed (at August 2021).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00760396 Multiple-Dose Study of VGX-1027 in Healthy Subjects Phase 1 Interventional VGX Pharmaceuticals, LLC
NCT00627120 Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects Phase 1 Interventional VGX Pharmaceuticals, LLC
NCT04590547 GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) Phase 2 Interventional GeneOne Life Science, Inc.